Home › Funds › MPM BioImpact LLC › DBVT
MPM BioImpact LLC position in DBVT
DBV TECHNOLOGIES S A · Health Care
MPM BioImpact LLC reported holding 3,666,284 shares of DBVT (DBV TECHNOLOGIES S A) in its Q2 2026 13F filing — a position valued at US$60.1M, representing 3.67% of its reported portfolio and ranking #8 among its reported holdings. MPM BioImpact LLC has disclosed DBVT holdings in 5 of the last 5 reported quarters, going back to Q2 2025.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How MPM BioImpact LLC's DBVT position evolved
MPM BioImpact LLC first disclosed a stake in DBVT in Q2 2025 at 1,054,504 shares (US$9.6M). The position peaked in Q1 2026 at 5,213,361 shares, worth US$108.9M. Across 5 filings, MPM BioImpact LLC increased the stake 1 time(s), trimmed it 2 time(s) and left it unchanged 1 time(s). The most recent filing (Q2 2026) shows 3,666,284 shares valued at US$60.1M — a reduction of -1,547,077 shares quarter over quarter.. Notable position changes include a 423% increase in Q1 2026 (shares fell 21% over the following quarter), a 30% trim in Q2 2026 (shares fell 28% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q2 2025 | 1.05M | $9.65M | New |
| Q3 2025 | 1.05M | $10.55M | Hold |
| Q4 2025 | 996.83K | $19.11M | Reduce |
| Q1 2026 | 5.21M | $108.91M | Add |
| Q2 2026 | 3.67M | $60.13M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About DBVT and 13F data
DBVT (DBV TECHNOLOGIES S A) is a Health Care company. 57 other funds we track also report a position in DBVT — the largest reported positions include Siren, L.L.C. (US$30.5M), Vivo Capital, LLC (US$30.3M), PERCEPTIVE ADVISORS LLC (US$27.1M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding DBVT
- Siren, L.L.C. 1.86M sh · $30.46M · Q2 2026
- Vivo Capital, LLC 1.84M sh · $30.25M · Q2 2026
- PERCEPTIVE ADVISORS LLC 1.65M sh · $27.11M · Q2 2026
- Logos Global Management LP 915.00K sh · $15.01M · Q2 2026
- Patient Square Capital LP 909.47K sh · $14.92M · Q2 2026
- Octagon Capital Advisors LP 574.20K sh · $9.42M · Q2 2026
- Redmile Group, LLC 410.44K sh · $6.73M · Q2 2026
- Elmind Capital, LP 265.00K sh · $4.35M · Q2 2026
- Ishara Investments LP 184.50K sh · $3.03M · Q2 2026
- Yiheng Capital Management, L.P. 170.14K sh · $2.79M · Q2 2026
- GREAT POINT PARTNERS LLC 156.91K sh · $2.57M · Q2 2026
More on MPM BioImpact LLC
FAQ
How long has MPM BioImpact LLC held DBVT?
MPM BioImpact LLC has disclosed DBVT holdings in 5 of the last 5 reported quarters, going back to Q2 2025.
What is MPM BioImpact LLC's current position in DBVT?
As of Q2 2026, MPM BioImpact LLC holds 3.67M shares of DBVT (DBV TECHNOLOGIES S A), valued at $60.13M, representing 3.67% of its reported portfolio and ranking #8.
Has MPM BioImpact LLC been buying or selling DBVT?
In the latest 13F filing (Q2 2026), MPM BioImpact LLC reduced its position in DBVT. The position peaked in Q1 2026 at 5.21M shares.
Which other funds hold DBVT?
Other major institutional holders of DBVT include Siren, L.L.C., Vivo Capital, LLC, PERCEPTIVE ADVISORS LLC, among 57 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.